Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 6.013 billion yuan, a year-on-year increase of 18.3%, aligning with forecast values and exceeding early-year high single-digit expectations [1] - The net profit was 492 million yuan, a year-on-year decrease of 28.0%, which is the midpoint of the forecast range, attributed to increased management expenses and legal compliance costs [1] - Adjusted net profit was 737 million yuan, a year-on-year decline of 2.1%, also within the forecast range [1] - The company's gross margin for H1 was 37.3%, a decrease of 0.5 percentage points year-on-year, while the adjusted net profit margin was 12.3%, an increase of 2.5 percentage points year-on-year [1] Group 2: Business Segments - The self-owned brand business generated revenue of 1.274 billion yuan in H1, a year-on-year increase of 14.1%, with European revenue growing by 15.1% [1] - The To B business revenue was 4.739 billion yuan, a year-on-year increase of 19.5%, with European revenue rising by 38.0% [2] - The HNB market is experiencing rapid growth, with the company collaborating with British American Tobacco on the HNB product gloHilo, which received positive feedback during trials in Japan [2] Group 3: Market Outlook and Projections - The company is adjusting its profit forecasts due to the impact of incentive amortization and other expenses, projecting net profits of 1.33 billion, 2.22 billion, and 2.89 billion yuan for 2025-2027 [3] - The company maintains a "buy" rating, with projected P/E ratios of 100, 60, and 46 for the respective years [3]

Core Viewpoint - Smoore International, the world's largest electronic vapor product manufacturer, reported a revenue of 6.013 billion RMB for the first half of 2025, an increase of 18.3% year-on-year, while adjusted net profit decreased by 2.1% to 737 million RMB [1] Group 1: Financial Performance - The company proposed an interim dividend of 0.20 HKD per share, with a payout ratio increasing to 225.1%, compared to approximately 38.7% in the same period of 2024 [1] - The self-owned brand business generated approximately 1.274 billion RMB in revenue, a year-on-year increase of about 14.1%, accounting for approximately 21.2% of total revenue [1] Group 2: Brand and Market Performance - The self-owned brand "Lanzhi" in mainland China generated approximately 31 million RMB in revenue, showing a significant year-on-year growth of about 2595.2% [2] - The "Lanzhi" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification, being adopted by over 100 private institutions [2] Group 3: Business Segments - The To B (business-to-business) segment recorded revenue of approximately 4.739 billion RMB, a year-on-year increase of about 19.5%, driven mainly by the recovery of the electronic vapor business [2] - The company successfully supported key clients in launching a series of innovative compliant products in response to regulatory changes in the European market, leading to strong order growth [2] Group 4: Research and Development - The company focused on enhancing R&D efficiency, prioritizing investments in heated non-combustible (HNB) products and vapor medical applications, achieving several breakthroughs in R&D [3] - A significant milestone was the successful support of a strategic client in launching a high-end HNB product series in key markets, with plans for a nationwide launch in Japan by September 2025 [3] Group 5: Future Outlook - The company aims to continue leveraging technological innovation as a foundation, focusing on electronic vapor, heated non-combustible, special-purpose vapor products, vapor medical, and vapor beauty sectors to provide comprehensive vapor technology solutions [3]

Group 1 - The core viewpoint of the report indicates that Smoore International's revenue increased by 18% year-on-year in the first half of the year, while net profit after tax decreased by 2.5%, which is roughly in line with expectations [1] - The company is expected to see a slight improvement in revenue growth for the full year, but profit margins are anticipated to remain under pressure [1] - Due to the weak profitability of Smoore International, the earnings per share estimates for the next two years have been lowered by 5% and 10%, respectively, and the target price has been reduced by 6% to HKD 8.7, maintaining an "underperform" rating [1]

Core Viewpoint - Smoore International (06969) experienced a significant stock price fluctuation, initially rising over 8% before closing up 6.25%, but later fell by 5.88% to HKD 22.08 with a trading volume of HKD 683 million [1] Financial Performance - For the first half of 2025, Smoore International reported revenue of RMB 6.013 billion, representing a year-on-year increase of 18.3% [1] - Adjusted profit for the period was RMB 737 million, a decrease of 2.1% year-on-year [1] - Net profit for the period was RMB 492 million, reflecting a significant year-on-year decline of 27.96% [1] Dividend Announcement - In celebration of the company's fifth anniversary since its listing, the board declared an interim dividend of HKD 0.20 per share for the six months ending June 30, 2025, compared to HKD 0.05 per share in the same period last year [1] Analyst Insights - According to a report from Bank of America Securities, the company is expected to see a slight improvement in annual revenue growth, but profit margins are anticipated to remain under pressure [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a recovery in the European electronic vaporization market, and the HNB (Heat-not-Burn) segment is expected to release profit elasticity [8] - The company's revenue for the first half of 2025 reached 6.013 billion yuan, a year-on-year increase of 18.3%, aligning with forecast values and exceeding initial high single-digit expectations [8] - The HNB market is in a rapid growth phase, with the company collaborating with British American Tobacco on new products, indicating potential for future profit contributions [8] Financial Summary - Total revenue projections for the company are as follows: - 2023A: 11.177 billion yuan - 2024A: 11.799 billion yuan - 2025E: 13.722 billion yuan - 2026E: 16.166 billion yuan - 2027E: 18.395 billion yuan - Year-on-year growth rates are projected at (8.06)%, 5.56%, 16.30%, 17.81%, and 13.79% respectively [1] - Net profit attributable to the parent company is forecasted as: - 2023A: 1.645 billion yuan - 2024A: 1.303 billion yuan - 2025E: 1.329 billion yuan - 2026E: 2.217 billion yuan - 2027E: 2.891 billion yuan - Year-on-year growth rates are projected at (34.47)%, (20.78)%, 1.96%, 66.84%, and 30.40% respectively [1] - The latest diluted EPS (Earnings Per Share) is projected as follows: - 2023A: 0.27 yuan - 2024A: 0.21 yuan - 2025E: 0.21 yuan - 2026E: 0.36 yuan - 2027E: 0.47 yuan [1] - The P/E (Price-to-Earnings) ratios at current price and latest diluted EPS are: - 2023A: 80.56 - 2024A: 101.69 - 2025E: 99.73 - 2026E: 59.78 - 2027E: 45.84 [1]

Core Viewpoint - Bank of America Securities reports that Smoore International (06969) experienced an 18% year-on-year increase in revenue for the first half of the year, while net profit after tax fell by 2.5%, which is roughly in line with expectations [1] Financial Performance - Smoore International's revenue growth for the full year is expected to improve slightly, but profit margins are anticipated to remain under pressure [1] - The bank has lowered its earnings per share estimates for the company by 5% and 10% for the current and next year, respectively [1] Target Price Adjustment - The target price for Smoore International has been reduced by 6% to HKD 8.7 [1] - The rating has been reaffirmed as "underperform" [1]

Core Viewpoint - Bank of America Securities reports that Smoore International (06969) experienced an 18% year-on-year increase in revenue for the first half of the year, while after-tax net profit declined by 2.5%, which is roughly in line with expectations [1] Group 1 - The company is expected to see a slight improvement in revenue growth for the full year, but profit margins are anticipated to remain under pressure [1] - Due to the weak profitability of Smoore International, the earnings per share estimates for the next two years have been lowered by 5% and 10% respectively [1] - The target price has been reduced by 6% to HKD 8.7, and the rating has been reiterated as "underperform" [1]

Core Viewpoint - Smoore International (06969) experienced a significant stock price fluctuation, initially rising over 8% before closing up 6.25%, but later falling 5.88% to HKD 22.08, with a trading volume of HKD 683 million [1] Financial Performance - For the first half of 2025, Smoore International reported revenue of RMB 6.013 billion, representing a year-on-year increase of 18.3% [1] - Adjusted profit for the period was RMB 737 million, a decrease of 2.1% year-on-year [1] - Net profit for the period was RMB 492 million, reflecting a significant year-on-year decline of 27.96% [1] Dividend Announcement - In celebration of its fifth anniversary since listing, the board declared an interim dividend of HKD 0.20 per share for the six months ending June 30, 2025, compared to HKD 0.05 per share in the same period last year [1] Analyst Insights - According to a report from Bank of America Securities, the company is expected to see slight improvement in annual revenue growth, but profit margins are anticipated to remain under pressure [1]

Core Viewpoint - Smoore International (06969) experienced a significant stock price fluctuation, initially rising over 8% before closing up 6.25%, but later fell by 5.88% to HKD 22.08 with a trading volume of HKD 683 million [1] Financial Performance - For the first half of 2025, Smoore International reported revenue of RMB 6.013 billion, representing a year-on-year increase of 18.3% [1] - Adjusted profit for the period was RMB 737 million, a decrease of 2.1% year-on-year [1] - Net profit for the period was RMB 492 million, reflecting a significant year-on-year decline of 27.96% [1] Dividend Announcement - In celebration of its fifth anniversary since listing, the board declared an interim dividend of HKD 0.20 per share for the six months ending June 30, 2025, compared to HKD 0.05 per share in the same period last year [1] Analyst Insights - According to a report from Bank of America Securities, the company is expected to see slight improvement in annual revenue growth, but profit margins are anticipated to remain under pressure [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company reported a revenue of 60.13 billion yuan for the first half of 2025, representing an 18.3% year-on-year growth. Gross profit reached 22.44 billion yuan, up 16.6%, with a gross margin of 37.3%, slightly down by 0.5 percentage points. However, net profit decreased by 28.0% to 4.92 billion yuan, and adjusted net profit was 7.37 billion yuan, down 2.1% [1][5]. - The company's self-owned brand business, primarily from electronic vapor products and vapor beauty products, generated 12.74 billion yuan in revenue, a 14.1% increase, accounting for 21.2% of total revenue. The European market contributed 10.69 billion yuan, up 15.1%, while the U.S. market saw a decline of 6.7% to 1.74 billion yuan. Notably, the Chinese market surged by 2595.2% to 306.18 million yuan, driven by the sales of the vapor beauty product "Lan Zhi" [2][3]. - The company is experiencing a recovery in its vapor electronic cigarette business, supported by stricter regulations against non-compliant products in global markets. This regulatory environment is expected to sustain growth in both self-owned brand and enterprise client businesses [3][4]. Segment Summaries - **HNB Products**: The company successfully supported strategic clients in launching the high-end HNB product Hilo series, which will be launched nationwide in Japan in September 2025. The company is committed to ongoing R&D in HNB products to address user pain points [4]. - **Vapor Medical**: The subsidiary, Chuan Si Bio, is focused on developing leading generic drugs for asthma and COPD in the U.S. and Europe, with plans for further collaboration with international pharmaceutical companies [4]. - **Vapor Beauty**: The "Lan Zhi" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification, with over 100 private institutions procuring it [4]. Profit Forecast and Investment Recommendations - The company is positioned as a global leader in vapor technology solutions, with increasing competitive advantages. The report anticipates significant contributions from HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 set at 14.72 billion, 19.79 billion, and 26.63 billion yuan, respectively, reflecting year-on-year growth rates of 34.40% and 34.60% for 2026 and 2027 [5].